预约演示

Chutes & Ladders—New year, new CEO at Scorpion Therapeutics

2024-01-05

高管变更上市批准

None

Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.

Scorpion’s CEO, CMO out the door

Scorpion Therapeutics

Scorpionew year and change is afoot at Scorpion Therapeutics, with both former CEO Axel Hoos, M.D., Ph.D., and CMO Michael Streit, M.D., hitting the exits.

Scorpion Therapeutics has led the oncology company since July 2021, when he left GSK for Scorpion. At the time, Hoos had taken the reins from interim CEO Adam Friedman, M.D., Ph.D., who will now take back the top title, this time without the temporary designation. Friedman is part of Scorpion’s founding team and most recently served as the biotech’s president of corporate strategy and business development.

The Boston biotech is also replacing StScorpion Therapeuticsst to fill the company’s chief medical officer position. Streit joined in 2022 from Sanofi, where he had most recently served as vice president and senior project head.

Now, Mark Chao, M.D., Ph.D., will take over as CMO. He joins Scorpion from TenSixGSKn BioScorpionhe served as co-founder and CEO.Scorpion

But the changes don’t stop there. ScoStreithas also promoted Erica Jackson, Ph.D., to chief discovery officer. She prStreitly served as the compSanofiexecutive vice president of biology. Fierce Biotech

CRISPR hunts for new CMOScorpion TenSixteen Bio

CRISPR TherapeuticsScorpion

CRISPR Therapeutics Chief Medical Officer Phuong Khanh Morrow, M.D., is resigning—a decision that was announced six days after the company secured FDA approval for its Vertex-partnered gene therapy Casgevy.

CRISPR Therapeuticseady kicked off the search for a new CMO, a spokesperson told Fierce Biotech.

CRISPR Therapeuticss has a seasoned leadership team with extensive experience managing clinical development for CRISPR’s programs and is well positFDAed to successfullyVertexe the transition,” a spoCasgevyon said via email.

Morrow, who has been with the company since May 2022, will officially depart Jan. 26. Her resignation was not the result of any disagreement with the gene-editing company, according to CRISPR Tx.

BCRISPR Therapeuticswiss-American biotech, Morrow spent more than 10 years in various leadership roles at Amgen.CRISPRe Biotech

Long-time Evotec CEO steps down

EvotecAmgen

Evotec’s CEvotecner Lanthaler has resigned from his role before his expected end of term, which was set for March 2026, citing personal reasons.

Evotec Evotecler, who has led the German biotech since 2009, will serve as a strategic advisor to Evotec’s board, which has launched a search for a permanent CEO.

Evoteca successor is chosen, board member Mario Polywka will take on the role of interim CEO. Ploywka had served as Evotec’s chief operating officer from 2006 to 2018. Release

> LianBio CEO Yizhe Wang, Ph.D., is headed for the exits in pursuit of new opportunities. CEvotecnvestment Officer Adam Stone will be the interim chief while the search for a permanent replacement begins. Release

> Ex-Biogen CEO Michel Vounatsos has joined the board of Quris-AI. Former Merck regional president Yossi Ben Amram wEvoteco named president of the company. Release

> LianBioPharma has hired Bertil Lindmark, Ph.D., M.D., to serve as chief medical officer, taking the reins from Rohit Batta. Lindmark joins from Galecto, where he also held the CMO role, and has previous experience as AstraZeneca’s global vice president of clinical development for respiratory and inflammation. Release

> AppBiogenherapeutics has named Constantine Chinoporos as its new chief oMercking officer and chief business officer. He’s been a strategic advisor for Apollo Therapeutics since February 2023 after past c-suite roles at other biotechs. Disclosure

> Vicore Pharma CEO Mondher Mahjoubi has resigned to pursue a new gig at a larger pharmaceutical company, the European biotech announced. ChairmanGalecto-founder Hervé Brailly will be the interim leader while the searchAstraZenecaacement gets underway. Releaseinflammation

> Applied Therapeutics on Aniz Girach, M.D., as chief medical officer. Girach was previously CMO of fellow gene editing biotech ProQR until March 2023. RApollo Therapeutics

> Innate Pharma gig for Nathan Dowden, who’s been promoted at Entrada from chief operating officer to president and COO. He’s been with the company since 2019 after working at Rubius. Release

> SpliceBioMO Cedric O’Gorman, M.D., is leaving the company after one year. He previously was the chief medical officer at Alpha Cognition. Release

> After Zevra’s recent acquisition of Acer, Adrian Quartel, M.Entradal become the new chief medical officer. He was the CMO of Acer and was the chief medical officer of Adamis Rubius that. Release

> Relmadaharmaceuticals founder Harvey Berger, M.D., has been hired as the new CEO of Kojin Therapeutics. Kojin is backed bAlpha CognitionLeaps By Bayer and AbbVie’s venture arm. Release

> IncludZevra Radionetics Oncology’s lAcert financing announcement was news that the biotech has brought on Paul Grayson as CEOAcer was most recently president and CEO of fellow oncology company Tentarix Biotherapeutics. Release

> ARIAD Pharmaceuticalss has tapped Minji Kim, Ph.D., to serve as chief business officKojin TherapeuticsysKojin held the same role at Affamed TheraBayercs anAbbViepast experience at Jounce Therapeutics, Curis and Hoffmann-La Roche. Release

> ProMIS NeuroRadionetics Oncology on Neil Warma as interim CEO to replace Gail Farfel, Ph.D. Warma has been a director on the company’s board since 2022. ReleaseTentarix Biotherapeutics

> Mineralys Therapeuticsd former HemoShear CSO Brian Alvin Johns, Ph.D., for the same role. BeforMineralysar, he was VP of discovery aAffamed TherapeuticsaseJounce Therapeutics Curis Hoffmann-La Roche

> ProMIS Neurosciences., is joining ROME Therapeutics as chief scientific officer. She previously was CSO and oversaw R&D of two now-clinical-stage PARP inhibitors at Ribon Therapeutics. Release

> Briinostics vet Brian Kim is thHemoShear of genomics company Mission Bio, the company announced. HemoShearusly was CEO of Fortis Life Viivnce aGSKheld other leadership roles at Biosearch Technologies and PerkinElmer. Release

> SV Health Investors has appointed ROME Therapeutics managing partner and Jamil Beg as partner. The two will help steer the firm’s biotech portfoliPARP inhibitors PARPhich includes cRibon Therapeuticscle and Nimbus. Release

> CymaBay Therapeutics and former Chief Commercial Officer LewiMission Biotually agreed that Stuart would leave the company Fortis Life Science’s VP Liver Franchise Lead Ben KozubBiosearch Technologiesp of PerkinElmerorganization. Release

> SV Healthherapeutics has tapped Dale Curtis Hogue, Jr., to serve as director of the immuno-oncology company. Hogue most recently founded Dune Lake Capital and previously worked asBicycleor anNimbusat Discovery Capital Management. Release

> CymaBay Therapeuticshilippe Martin to lead the company’s research and development as chief R&D officer. Martin has clocked in past expCymaBay at Celgene and Schering-Plough (acquired by Merck). Release

> Alaunos Therapeutics.D., Ph.D., is moving from 4DMT’s board to its C-suite, being named chief scientific officer. Kasahara is a brain surgeon who previously worked at UCSF. ReleaseDiscovery Capital Management

> ViatrisTherapeutics’ next chief scientific officer and head of research and development will be Aarif Khakoo, M.D., who joins the CRISPR genetic Celgenees coSchering-Ploughco Life SciencMercklso joining the biotech is Maria Mirotsou, Ph.D., as vice president of discovery biology. Release

> Eterna Therapeutics has picked Sanjeev Luther as its next CEO, as of Jan. 1. He succeeds Matt Angel, Ph.D. Luther has spent the past 30 years at various roles across bUCSFarma, most recently as CEO at Cornerstone Pharmaceuticals. Release

> Scribe Therapeuticshe new chief business officer for German biotech Eleva, which has a moss-based platform that develops complex pCRISPRs for treatment of diseases. RelCalico Life Sciences

> Eterna Therapeuticsics has named Mehdi Paborji, Ph.D., as senior vice president of technical operations to oversee CMC and manufacturing for the biotech’s nanomedicines. ReleaseCornerstone Pharmaceuticals

> Deka Biosciences has tapped Stanley Frankel, M.D., to serve as senior clinical advisor, interim chief medical officer and scientific advisory board member. The hematologist-oncologist joins Deka with past experience as SVP, global drug development for cell therapy for BMS following the 2019 acquisition of Celgene. Release

> Ashvattha Therapeuticscs has chosen J. Robert Coleman, Ph.D., to lead the biotech as CEO. Before joining HERVOLUTION, Coleman co-founded Codagenix and served as the company’s CEO for 12 years. Release

> Deka Biosciencesas appointed clinical radiologist Eyal Morag, M.D., to be the company’s chief medical officer. Morag joins from Microbot Medical, where he was also CMO, and currently serves Dekacientific and medical advisory roles at Aidoc Medical, Vortex Imaging and HBMSRad. ReleaseCelgene